JaLCDOI 10.18926/AMO/55858
フルテキストURL 72_2_175.pdf
著者 Hirata, Takeshi| Hanamoto, Masanori| Ogura, Kazuma| Hayashi, Nobuki| Takamura, Kosuke| Edamura, Kohei| Ebara, Shin| Saika, Takashi|
抄録 There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second-line or salvage therapy for advanced UC.
キーワード urothelial carcinoma gemcitabine cisplatin paclitaxel second-line salvage
Amo Type Original Article
発行日 2018-04
出版物タイトル Acta Medica Okayama
72巻
2号
出版者 Okayama University Medical School
開始ページ 175
終了ページ 179
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29674766